Chiasma Inc (NASDAQ:CHMA) reached a new 52-week high on Monday . The stock traded as high as $3.55 and last traded at $3.55, with a volume of 768 shares. The stock had previously closed at $3.35.

Chiasma (NASDAQ:CHMA) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, hitting the consensus estimate of ($0.36).

In related news, Director Scott Minick acquired 25,000 shares of Chiasma stock in a transaction that occurred on Thursday, September 20th. The stock was acquired at an average price of $3.08 per share, with a total value of $77,000.00. Following the completion of the acquisition, the director now directly owns 62,531 shares of the company’s stock, valued at approximately $192,595.48. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.20% of the company’s stock.

A hedge fund recently bought a new stake in Chiasma stock. Sofinnova Ventures Inc purchased a new stake in Chiasma Inc (NASDAQ:CHMA) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,630,221 shares of the biotechnology company’s stock, valued at approximately $2,445,000. Chiasma comprises approximately 0.4% of Sofinnova Ventures Inc’s portfolio, making the stock its 16th biggest position. Sofinnova Ventures Inc owned 6.69% of Chiasma as of its most recent filing with the SEC. 60.75% of the stock is currently owned by hedge funds and other institutional investors.

About Chiasma (NASDAQ:CHMA)

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Recommended Story: Google Finance Portfolio Workaround

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.